Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure
Collaborative Research Group · Ohio Heart & Vascular Center · +2 more institutions
Abstract
BACKGROUND: Preclinical and preliminary clinical data have suggested that tumor necrosis factor-alpha (TNFalpha) may play a role in the evolution and progression of heart failure and that inhibition of TNFalpha may favorably modify the course of the disease. We evaluated the efficacy and safety of infliximab, a chimeric monoclonal antibody to TNFalpha, in patients with moderate-to-severe heart failure. METHODS AND RESULTS: One hundred fifty patients with stable New York Heart Association class III or IV heart failure and left ventricular ejection fraction
Citation impact
- FWCI
- 47.83
- Percentile
- 100%
- References
- 40
Authors
5- ESEugene S. ChungCorresponding
Collaborative Research Group, Ohio Heart & Vascular Center, Columbia University, The University of Texas Health Science Center at Houston
- MPMilton Packer
Collaborative Research Group, Ohio Heart & Vascular Center, Columbia University, The University of Texas Health Science Center at Houston
- KHKim Hung Lo
Collaborative Research Group, Ohio Heart & Vascular Center, Columbia University, The University of Texas Health Science Center at Houston
- AAAdedigbo A. Fasanmade
Collaborative Research Group, Ohio Heart & Vascular Center, Columbia University, The University of Texas Health Science Center at Houston
- JTJames T. Willerson
Collaborative Research Group, Ohio Heart & Vascular Center, Columbia University, The University of Texas Health Science Center at Houston
Topics & keywords
- Infliximab
- Medicine
- Ejection fraction
- Heart failure
- Hazard ratio
- Placebo
- Internal medicine
- Clinical endpoint
- Good health and well-being